Brigham and Women's Hospital, Boston, MA.
Harvard Medical School, Boston, MA.
AMIA Annu Symp Proc. 2021 Jan 25;2020:1200-1209. eCollection 2020.
The objective was to re-tool the existing claims-based measure NQF2940 "Use of Opioids at High Dosage in Persons Without Cancer" to an electronic clinical quality measure (eCQM) for use by orthopedic practices to assess potentially inappropriate high-dose post-operative opioid prescribing practices. Measure specifications were revised based on stakeholder feedback, initial testing and a targeted review of the literature. The eCQM was developed and alpha tested on 9,108 opioid-naive patients who received an elective primary total hip or total knee arthroplasty at Mass General Brigham formerly Partners HealthCare System) from 2016 to 2018. Thirty-eight percent of patients were prescribed high doses (defined as an average daily dose ≥90 morphine milligram equivalents) for the duration of their post-operative opioid prescriptions, demonstrating that this is a meaningful performance measure with substantial opportunity for improvement. National implementation and reporting of this eCQM could be used to facilitate quality improvement to deliver standardized, safe and high-quality care.
目的是对现有的基于索赔的衡量标准 NQF2940“无癌症患者大剂量使用阿片类药物”进行重新调整,以成为一种电子临床质量衡量标准(eCQM),供骨科实践使用,以评估潜在的不适当大剂量术后阿片类药物处方实践。根据利益相关者的反馈、初步测试和对文献的有针对性审查,对衡量标准规范进行了修订。该 eCQM 是在 2016 年至 2018 年间在马萨诸塞州综合医院(前身为 Partners HealthCare 系统)接受择期初次全髋关节或全膝关节置换术的 9108 名阿片类药物初治患者身上开发和进行 alpha 测试的。38%的患者在术后阿片类药物处方期间被开具高剂量(定义为平均每日剂量≥90 吗啡毫克当量),这表明这是一个有意义的绩效衡量标准,有很大的改进空间。该 eCQM 的全国实施和报告可以用于促进质量改进,以提供标准化、安全和高质量的护理。